List view / Grid view
7 November 2014 | By Invetech and Argos Therapeutics
Invetech and Argos Therapeutics to partner on automated production of personalized immunotherapies for cancer and infectious diseases...
Janssen Research & Development, LLC (Janssen) today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO® (bedaquiline) in the STREAM Study. The STREAM study is an ongoing, multi-centre international randomized controlled trial to evaluate a standardized treatment regimen of anti-tuberculosis drugs for patients…
5 November 2014 | By Roche
Addressing Asia Pacific’s growing demand for diagnostics...
5 November 2014 | By Allied Minds
Allied Minds, an innovative U.S. science and technology development and commercialization company, announced that Donna See, former Director of Licensing and Strategic Initiatives at Columbia University’s technology transfer office, has joined as Vice President to lead the firm’s partnerships with U.S. research universities...
5 November 2014 | By Public Health England
Around half of the people living with hepatitis C infections don’t know it, according to a new publication out today from Public Health England (PHE), “Shooting Up: Infections among people who inject drugs in the United Kingdom 2013”...
5 November 2014 | By Micreos
Micreos, a Dutch biotech company, has developed Staphefekt™, a bacteria-killing enzyme specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA)...
5 November 2014 | By TxCell
TxCell (FR0010127662 - TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014...
5 November 2014 | By BerGenBio AS
BerGenBio AS announces that the first patient has been dosed in its multi-centre Phase 1b trial (BGBC003) of BGB324, a selective inhibitor of Axl, in patients with acute myeloid leukaemia (AML) at Haukeland University Hospital in Bergen, Norway...
CAMO Software, leaders in multivariate data analysis software, and Lonza Group, a leading supplier to the pharma, biotech and specialty ingredients markets, have entered into an agreement where CAMO Software will deliver a PAT software solution for collecting, handling, storing, monitoring and modeling of PAT data. The solution will complement…
5 November 2014 | By Moberg Pharma
Moberg Pharma AB announced that it entered into a services agreement with Emerson Healthcare, a division of Emerson Group, who will provide certain logistical services and all order to cash functions for retailer and wholesaler customers in the U.S...
5 November 2014 | By AOP Orphan
The pharmaceutical company AOP Orphan, a European pioneer in the field of rare diseases, is expanding its sales area for the special preparation Thromboreductin® to include the large Russian market...
5 November 2014 | By The Institute of Cancer Research, London
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert has said...
5 November 2014 | By myoscience
myoscience, inc. is pleased to announce the appointment of Jeffrey Gold as Chief Executive Officer effective immediately...
4 November 2014 | By Photocure
Phase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix...
4 November 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced the establishment of a wholly owned subsidiary in The United Kingdom (UK) to serve customers and patients in the UK and Ireland...
